Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 14/20 | 0.48 |
| ▸ | HTR2B | P41595 | 14/20 | 0.48 |
| ▸ | HTR2A | P28223 | 11/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.31 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.31 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.30 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.30 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14110389 | 0.89 | HTR2B (0.51) | HTR2CHTR2BHTR2AACHECDK5 | |
| SCHEMBL3564664 | 0.89 | HTR2B (0.51) | HTR2CHTR2BHTR2AACHECDK5 | |
| SCHEMBL3559813 | 0.88 | HTR2C (0.50) | HTR2CHTR2BHTR2A | |
| SCHEMBL3554428 | 0.88 | HTR2C (0.39) | HTR2CHTR2BHTR2APARP10PARP11 | |
| SCHEMBL3558747 | 0.88 | HTR2C (0.53) | HTR2CHTR2BHTR2A | |
| SCHEMBL3553219 | 0.85 | HTR2C (0.43) | HTR2CHTR2BHTR2A | |
| SCHEMBL3557891 | 0.84 | HTR2C (0.48) | HTR2CHTR2BHTR2APARP1 | |
| SCHEMBL3556795 | 0.80 | HTR2C (0.48) | HTR2CHTR2BHTR2APARP10PARP11 | |
| SCHEMBL3556629 | 0.80 | HTR2C (0.48) | HTR2CHTR2BHTR2AACHEPARP1 | |
| SCHEMBL3551773 | 0.79 | HTR2C (0.53) | HTR2CHTR2BHTR2AACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1675859-B1 | MODULATORS OF SEROTONIN RECEPTORS | BRISTOL MYERS SQUIBB CO (US) | 2012-12-05 | — | — | EP | claimed |
| US-20050080074-A1 | Modulators of serotonin receptors | BRISTOL-MYERS SQUIBB COMPANY | 2005-04-14 | — | — | US | claimed |
| EP-1675859-B1 | MODULATORS OF SEROTONIN RECEPTORS | BRISTOL MYERS SQUIBB CO (US) | 2012-12-05 | — | — | EP | disclosed |
| US-7812024-B2 | Modulators of serotonin receptors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-10-12 | — | — | US | disclosed |
| US-20070213337-A1 | MODULATORS OF SEROTONIN RECEPTORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-09-13 | — | — | US | disclosed |
| US-7244843-B2 | Modulators of serotonin receptors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-17 | — | — | US | disclosed |
| US-20050080074-A1 | Modulators of serotonin receptors | BRISTOL-MYERS SQUIBB COMPANY | 2005-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213337-A1 | MODULATORS OF SEROTONIN RECEPTORS | HTR5A, HTR1A, HTR2A | HTR2C 5/4885HTR2B 4/4885HTR2A 3/4885 |
| US-20050080074-A1 | Modulators of serotonin receptors | HTR5A, HTR1A, HTR2B | HTR2C 6/4885HTR2B 3/4885HTR2A 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.